文献速递甲状腺疾病

新型酪氨酸激酶抑制剂可通过内源性钠/碘同向转运体表达增强未分化甲状腺癌的放射性碘摄取

A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
PubMed 文献 · Thyroid · 2020-02-14

本研究通过高通量筛选鉴定新型酪氨酸激酶抑制剂CTOM-DHP,在8505C未分化甲状腺癌细胞中证实其可增强钠/碘同向转运体(NIS)表达及功能,并增加放射性碘摄取与细胞毒性;体内实验亦显示CTOM-DHP可提高NIS启动子活性和放射性碘亲和力,并改善131I治疗效果。

要点

  • CTOM-DHP在8505C未分化甲状腺癌细胞中增强NIS启动子活性及mRNA和蛋白表达。
  • CTOM-DHP增加125I摄取和131I细胞毒性,与抑制PI3K/Akt和MAPK通路相关。
  • 体内实验显示CTOM-DHP提高NIS启动子活性和放射性碘亲和力,改善131I疗效。

核心结论

  • CTOM-DHP是一种新发现的酪氨酸激酶抑制剂,可增强内源性NIS表达,是恢复未分化甲状腺癌放射性碘亲和力的有前景化合物。

研究设计与样本

  • 采用高通量筛选系统鉴定新型酪氨酸激酶抑制剂CTOM-DHP,在8505C未分化甲状腺癌细胞中暴露于不同浓度和时间点,选择12.5和25 μM及72小时孵育条件进行后续NIS启动子试验及NIS mRNA和蛋白表达实验,并评估碘代谢相关因子、信号通路、体外和体内放射性碘摄取及131I细胞毒性效应。

主要发现

  • 启动子试验及mRNA和蛋白表达分析证实,CTOM-DHP处理8505C未分化甲状腺癌细胞后NIS表达增强。
  • CTOM-DHP处理强力增加其他甲状腺特异性蛋白和与碘代谢相关的甲状腺转录因子表达。
  • NIS功能增强表现为125I摄取和131I细胞毒性增加。
  • 内源性NIS表达增加与PI3K/Akt和MAPK信号通路抑制相关。
  • 体内实验结果亦显示CTOM-DHP处理增加NIS启动子活性和放射性碘亲和力,且131I介导的治疗效应在肿瘤异种移植小鼠模型中优先改善。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Radioactive iodine (RAI) therapy is an important strategy in the treatment of thyroid cancer. However, anaplastic thyroid cancer (ATC), a rare malignancy, exhibits severe dedifferentiation characteristics along with a lack of sodium iodide symporter (NIS) expression and function. Therefore, RAI therapy is ineffective and contributes toward poor prognosis of these patients. Recently, small-molecule tyrosine kinase inhibitors (TKIs) have been used to treat thyroid cancer patients for restoring NIS expression and function and RAI uptake capacity. However, most results reported thus far are associated with differentiated thyroid cancer. In this study, we identified a new TKI and investigated its effects on cell redifferentiation, NIS function, and RAI therapy in ATC. Methods: We identified a new TKI, "5-(5-{4H, 5H,6H-cyclopenta[b]thiophen-2-yl}-1,3,4-oxadiazol-2-yl)-1-methyl-1,2-dihydropyridin-2-one" (CTOM-DHP), using a high-throughput screening system. CTOM-DHP was exposed to 8505C ATC cells at different concentrations and time points. Concentrations of 12.5 and 25 μM and an incubation time of 72 hours were chosen as the conditions for subsequent NIS promoter assays and NIS mRNA and protein expression experiments. In addition, we examined factors related to iodide metabolism after CTOM-DHP treatment as well as the signaling pathways mediating the effects of CTOM-DHP on endogenous NIS expression. RAI uptake and 131I cytotoxicity effects caused by CTOM-DHP pretreatment were also evaluated in vitro and in vivo. Results: Promoter assays as well as mRNA and protein expression analyses confirmed that NIS expression was augmented by treatment of 8505C ATC cells with CTOM-DHP. Moreover, CTOM-DHP treatment robustly increased the expression of other thyroid-specific proteins and thyroid transcription factors related to iodide metabolism. Enhancement of NIS function was demonstrated by an increase in 125I uptake and 131I cytotoxicity. Increased endogenous NIS expression was associated with the inhibition of PI3K/Akt and MAPK signaling pathways. In vivo results also demonstrated an increase in NIS promoter activity and RAI avidity in response to CTOM-DHP treatment. Furthermore, 131I-mediated therapeutic effects preferentially improved in a tumor xenograft mice model. Conclusions: CTOM-DHP, a new TKI identified in this study, enhances endogenous NIS expression and thereby is a promising compound for restoring RAI avidity in ATC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Oh JM, Baek SH, Gangadaran P, et al. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer. Thyroid. 2020. PMID: 31928162. doi:10.1089/thy.2018.0626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。